Business Wire

ADVA

15.12.2020 09:02:11 CET | Business Wire | Press release

Share
ADVA launches new generation of edge and access clocks for 5G network timing

ADVA (FSE: ADV) today launched a unique set of edge and access network synchronization devices with enhanced capabilities for next-generation applications such as 5G. The latest Oscilloquartz solutions address key challenges for a wide range of industries by bringing new levels of timing accuracy and resilience to edge networks. The OSA 5412 and 5422 offer precise phase, frequency and time-of-day synchronization and can be used for time-as-a-service applications. For the first time, communication service providers, enterprises, broadcast networks and power utilities can deploy synchronization technology at the edge that features multi-band GNSS receivers for nanosecond accuracy. The OSA 5412 and 5422 utilize in-service sync probing and assurance as well as innovative GNSS assurance capabilities. The products also provide support for eight field-upgradeable 10Gbit/s ports, ensuring the scale and efficiency needed for next-generation smart grids, industrial IoT applications and 5G connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005081/en/

“Our latest solutions build on the great success we’ve had with our access synchronization product line. Now operators can harness the power of multi-band GNSS receivers to deliver highly accurate, UTC-traceable timing at the network edge. That enables the availability and precision that will be essential for tomorrow’s services,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “By extending the feature set of our edge technology, we’re empowering CSPs to smoothly transition to the reliability and accuracy required for 5G and, at the same time, enabling our unique innovation to be used across a wide range of verticals. With support for 10Gbit/s and 1Gbit/s interfaces as well as hardware timestamping, our access timing products are the ultimate in future-proof, space-efficient synchronization.”

The OSA 5412 is a highly flexible access network synchronization solution that offers compact and cost-effective timing distribution and assurance. The OSA 5422 is engineered for the most extreme conditions. It meets stringent frequency and phase synchronization requirements, delivers the best holdover performance of any edge device on the market, and supports multiple legacy interfaces such BITS and IRIG. Both solutions address new ITU-T specifications, including for class A and B PRTCs, ePRTCs with strict holdover requirements, and the newly improved class C and D boundary clocks. They also feature onboard multi-band, multi-constellation GNSS receivers that overcome ionospheric delay variation far more cost-efficiently than rival solutions using high-end rubidium oscillators. The OSA 5412 and 5422 support multiple PTP profiles, NTP and SyncE with the highest number of 1/10GbE ports on the market. What’s more, both devices are engineered with optional OLED display and with hot-swappable modules and power supplies to be easily upgraded in the field.

“Access grandmaster clocks need to meet stricter demands for accuracy and reliability than ever before, and many industries have their own specific set of stringent timing requirements. That’s why we’ve evolved our portfolio of edge and access network synchronization solutions for the specific challenges of the 5G era,” commented Gil Biran, general manager, Oscilloquartz, ADVA. “Our OSA 5412 and 5422 answer the most urgent timing needs of mission-critical infrastructure in multiple verticals. They provide nanosecond precision, an abundance of fan-out interface options and operational simplicity thanks to the management and monitoring capabilities of our Ensemble Controller with Sync Director. Operators of broadcast, healthcare, financial networks and more now have a straightforward and affordable path from legacy to next-generation timing.”

Further information on the OSA 5412 and 5422 is available in these slides: https://adva.li/osa-5412-5422-slides .

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz

Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye